

CMAB, Fapon join hands for biologic oncology asset

03 December 2019 | News

CMAB will provide a full range of development and manufacturing services for Fapon Biopharma's biologic drug project



CMAB Biopharma Inc., a pure-play, biologics contract manufacturing and development organization (CDMO) and Shenzhen Fapon Biopharma Inc., an innovative biopharmaceutical company, announced a comprehensive strategic agreement for the development and manufacturing of an undisclosed biologic drug project.

According to the agreement, Fapon Biopharma will avail of the fully integrated CMC process development and manufacturing platform, the European QP audited product quality system and the experienced regulatory team in dual IND filings in both China and the United States at CMAB.

"We are very excited and proud to be able to closely participate in this meaningful biologic drug development project of Fapon Biopharma. The founding aspiration and goal of CMAB is to make our customers successful as quickly as possible. We are willing and confident to work with innovative biopharmaceutical companies such as Fapon Biopharma to overcome technical difficulties, reduce R&D costs, reach milestones quickly and of high quality, and create sustainable value for customers", said Dr. Yongzhong Wang, CEO of CMAB Biopharma.